The Q1 miss may pressure the stock near-term, but focus should shift to upcoming PDUFA decisions and GTX-102 Phase 3 readout. Traders should weigh the weak quarter against pipeline catalysts; a beat on any of these could reverse sentiment.
RARE drugs
RARE drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $25.93entry
- T+1 · 6mo ago 0.00%α +0.33% · $25.93
- T+5 · 6mo ago +3.51%α +2.38% · $26.84
- T+20 · 6mo ago −13.57%α −16.36% · $22.41
- T+60 · 4mo ago −3.93%α −5.99% · $24.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expectations. Despite reaffirming full-year 2026 guidance of $730M-$760M revenue, the weak quarter and wider operating loss of $305M signal near-term headwinds, though upcoming PDUFA dates for DTX401 and UX111 provide potential catalysts.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $136M, down 2.2% YoY from $139M, missing consensus $158.4M
- Q1 2026 EPS -$1.84 vs consensus -$1.46; net loss $185M vs $151M YoY
- Reaffirmed full-year 2026 revenue guidance $730M-$760M and expense guidance
- R&D expenses $187M, up from $166M YoY; SG&A $88M flat
- Total operating expenses $305M included $30M restructuring and $30M stock-based compensation
- Cash and securities $534M; net cash used in operations $197M
- Two BLAs under FDA review with PDUFA dates: DTX401 (Aug 23, 2026) and UX111 (Sep 19, 2026)
- Phase 3 GTX-102 Angelman data expected H2 2026
Financial Impact
Revenue miss of ~$22M (14%) vs consensus; EPS miss of -$0.38 (26%) vs consensus
Risk Factors
- FDA delays or rejections for DTX401 or UX111
- Competition in Angelman syndrome and gene therapy
- Continued cash burn and need for additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288196 |
Track record
22 reports on RARE
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers